TITLE

Prescription Drugs: Many Factors Affected FDA's Approval of Selected 'Pipeline' Drugs: HEHS-00-140

PUB. DATE
August 2000
SOURCE
GAO Reports;8/10/2000, p1
SOURCE TYPE
Government Document
DOC. TYPE
Article
ABSTRACT
The Drug Price Competition and Patent Term Restoration Act of 1984 seeks to expand the availability of more effective and affordable drugs by providing the generic drug industry with a simplified and faster review process and brand-name drug companies with an extension of the existing 17-year patent protection. At the time of the law's enactment, drugs for which a patent had been issued and human trials begun were considered "pipeline" drugs and were limited to two-year patent extensions. Legislation (H. R. 1598 and S.1172) has been introduced to allow manufacturers of pipeline drugs to apply for a patent extension beyond that two-year limit. This report compares FDA review and approval times of pipeline drugs with other drugs and examines whether the two-year patent extension granted to pipeline drugs under current law is based on the average length of time for FDA approval of new drug applications. GAO found that approval times for the pipeline drugs on which the study focused were significantly longer than the corresponding average approval times, ranging from 17 to 65 months longer than the average time for comparable pipeline drugs. In general, delays in FDA approval resulted from concerns about safety and efficacy, chemical properties, and manufacturing procedures. Specific concerns varied by drug. Concerning the basis for the patent-extension limit, the legislative history of the 1984 Act does not clarify why a two-year limit for patent extension was chosen for pipeline drugs or why a five-year limit was chosen for other drugs.
ACCESSION #
18208802

 

Related Articles

  • EARNING EXCLUSIVITY: GENERIC DRUG INCENTIVES AND THE HATCH-WAXMAN ACT. Hemphill, C. Scott; Lemley, Mark A. // Antitrust Law Journal;Sep2011, Vol. 77 Issue 3, p947 

    No abstract available.

  • Generic Drug Industry Faces Regulatory and Patent Issues. Mirasol, Feliza // Chemical Market Reporter;04/12/99, Vol. 255 Issue 15, p4 

    Reports the delay in market entry of generic products that are prompting the generic drug industry to reevaluate and challenge regulatory and patent laws. Concerns of industry for the Waxman-Hatch Act of 1984; Information on the interim guidance released by the United States Food and Drug...

  • "At-risk" generic launches can be unpredictable. Kaufman, Michele B. // Formulary;May2010, Vol. 45 Issue 5, p165 

    The article discusses U.S. Food and Drug Administration (FDA) approval, or launch, of at-risk generic drugs. An at-risk generic drug can be approved by the FDA while the litigation of patent rights is still ongoing. According to the author, at-risk generic launches create an environment of...

  • HATCH-WAXMAN AND MEDICAL DEVICES. Wallenfelt, Brian P. // William Mitchell Law Review;2014, Vol. 40 Issue 4, p1407 

    The article discusses America's medical device approval process in relation to the U.S. Drug Price Competition and Patent Term Restoration (Hatch-Waxman) Act of 1984, and it mentions the regulation of class III medical devices, as well as generic drug laws and the U.S. Food and Drug...

  • Senators Reveal FOBs Bill.  // BioWorld Today;3/30/2009, Vol. 20 Issue 59, p5 

    The article reports on the bipartisan legislation for the approval of follow-on biologics (FOBs) or biogenerics. The bill, which will authorize the Food and Drug Administration (FDA) to approve biogenerics, was introduced by Senators Charles Schumer and Susan Collins and sponsored by Senators...

  • Generic Drugs Face Regulatory and Scientific Challenges. Wechsler, Jill // Pharmaceutical Technology;Aug2013, Vol. 37 Issue 8, p24 

    The article discusses regulatory and scientific challenges faced by generic drugs. It mentions about one-year anniversary of the Generic Drug User Fee Amendments (GDUFA) of 2012 by the U.S. Food and Drug Administration (FDA) mentioning that the agency collected 255 million dollars in user fees....

  • FDA ANDA Approvals Top 300 in '04 But Application Backlog Remains. Kelly, Cathy // Chemical Market Reporter;10/18/2004, Vol. 266 Issue 13, p10 

    The article reports that the number of full generic drug approvals reached 320 in fiscal year 2004, compared to 284 the previous year, according to the U.S. Food and Drug Administration's (FDA) Office of Generic Drugs. The tally for the most recent fiscal year marks a recovery from fiscal year...

  • The Effect of FDASIA on Inspections. Elder, David // Pharmaceutical Technology;Apr2013, Vol. 37 Issue 4, p138 

    The article provides an answer to a question on how the U.S. Food and Drug Administration Safety and Innovation Act (FDASIA) affects the inspection of generic-drug activities.

  • FDA set to control biogenerics approvals.  // Pharmaceutical Technology Europe;Apr2007, Vol. 19 Issue 4, p13 

    The article focuses on the Access to Life-Saving Medicine Act, legislation introduced by the U.S. government that could grant the Food and Drug Administration (FDA) the authority to approve generic versions of biologics. It would enable the agency to decide which clinical trials a generics firm...

Share

Read the Article

Other Topics